HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the closing of its underwritten initial public offering of common stock, including the underwriters’ exercise of their option to purchase an additional 1,102,500 shares at the public offering price of $19.00 per share. The underwriters’ option brought the total number of shares of common stock sold by Bellicum to 8,452,500 shares and increased the amount of gross proceeds raised in the offering to approximately $160.6 million, prior to deducting the underwriting discount and estimated expenses of the offering.
Help employers find you! Check out all the jobs and post your resume.
